Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

14.40
-0.3000-2.04%
Post-market: 14.450.0500+0.35%19:58 EDT
Volume:3.62M
Turnover:52.30M
Market Cap:1.64B
PE:-3.98
High:15.21
Open:15.20
Low:14.02
Close:14.70
Loading ...

Dyne Therapeutics' Chief Commercial Officer Johanna Friedl-Naderer Reports Disposal of Common Shares

Reuters
·
07 Jun

Dyne Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
06 Jun

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs

Reuters
·
06 Jun

Dyne Therapeutics Unveils Promising Preclinical Results for DYNE-302 in Treating Facioscapulohumeral Muscular Dystrophy

Reuters
·
05 Jun

Dyne Therapeutics, Inc. : Oppenheimer Cuts Target Price to $34 From $60

THOMSON REUTERS
·
02 Jun

Dyne Therapeutics (DYN) Receives a Buy from Evercore ISI

TIPRANKS
·
29 May

Stock Track | Dyne Therapeutics Soars 5.45% in Pre-Market on Positive Analyst Ratings and Strategic Progress

Stock Track
·
09 May

RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

Dyne Therapeutics: Strategic Advancements and Strong Financials Support Buy Rating

TIPRANKS
·
09 May

Dyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Dyne Therapeutics Reports Q1 2025 R&D Expenses Surge to $106.4M, Cash Reserves at $677.5M

Reuters
·
08 May

Dyne Therapeutics Q1 Basic EPS USD -1.05

THOMSON REUTERS
·
08 May

Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment

MT Newswires Live
·
24 Apr

BRIEF-Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy

Reuters
·
24 Apr

Dyne Therapeutics Receives European Medicines Agency (Ema) Orphan Drug Designation for Dyne-251 in Duchenne Muscular Dystrophy

THOMSON REUTERS
·
24 Apr

Dyne Therapeutics appoints Ranade as CBO, Batra as CSO

TIPRANKS
·
15 Apr

Press Release: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dow Jones
·
15 Apr

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
15 Apr

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m

Simply Wall St.
·
10 Apr

Dyne Therapeutics Inc : RBC Cuts Target Price to $36 From $41

THOMSON REUTERS
·
03 Apr